Design Therapeutics, Inc. (DSGN): Price and Financial Metrics

Design Therapeutics, Inc. (DSGN): $3.89

0.19 (+5.14%)

POWR Rating

Component Grades








Add DSGN to Watchlist
Sign Up

Industry: Biotech




#131 of 362

in industry

DSGN Price/Volume Stats

Current price $3.89 52-week high $8.47
Prev. close $3.70 52-week low $1.94
Day low $3.61 Volume 248,707
Day high $3.95 Avg. volume 264,773
50-day MA $3.16 Dividend yield N/A
200-day MA $3.21 Market Cap 219.76M

DSGN Stock Price Chart Interactive Chart >

Design Therapeutics, Inc. (DSGN) Company Bio

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.

DSGN Latest News Stream

Event/Time News Detail
Loading, please wait...

DSGN Latest Social Stream

Loading social stream, please wait...

View Full DSGN Social Stream

Latest DSGN News From Around the Web

Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 18, 2023

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | November 25, 2023

Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update

Pratik Shah Takes Helm as CEO, Company Eyes Long-Term Growth

Yahoo | November 15, 2023

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic

Yahoo | November 13, 2023

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | October 15, 2023

Read More 'DSGN' Stories Here

DSGN Price Returns

1-mo 2.37%
3-mo 62.76%
6-mo 91.63%
1-year -36.12%
3-year -79.81%
5-year N/A
YTD 46.79%
2023 -74.17%
2022 -52.08%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!